Small-molecule activation of p53 blocks hypoxia-inducible factor lα and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia

Molecular and Cellular Biology

Volumn 29, Issue 8, 2009, Pages 2243-2253

  Yang, Jun ^a   Ahmed, Afshan ^b   Poon, Evon ^b   Perusinghe, Nina ^a   De Haven Brandon, Alexis ^a   Box, Gary ^a   Valenti, Melanie ^a   Eccles, Suzanne ^a   Rouschop, Kasper ^c   Wouters, Brad ^d   Ashcroft, Margaret ^a,b,e  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Department of Metabolism and Experimental Therapeutics   (United Kingdom)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 BIS(5 HYDROXYMETHYL 2 THIENYL)FURAN; FURAN DERIVATIVE; GAMMA H2AX; HISTONE H2AX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 2ALPHA; NSC 652287; PHOSPHOTRANSFERASE; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; EUKARYOTIC INITIATION FACTOR-2; FURANS; HISTONES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PHOSPHORYLATION; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EUKARYOTA;

EID: 64649086259     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00959-08     Document Type: Article

References (51)

1. Achison, M., and T. R. Hupp. 2003. Hypoxia attenuates the p53 response to cellular damage. Oncogene 22:3431-3440.
2. Met is an important translation initiation intermediate in vivo. Genes Dev. 14:2534-2546.
3. Ashcroft, M., Y. Taya, and K. H. Vousden. 2000. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. 20:3224-3233.
4. Beuvink, I., A. Boulay, S. Fumagalli, F. Zilbermann, S. Ruetz, T. O'Reilly, F. Natt, J. Hall, H. A. Lane, and G. Thomas. 2005. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120:747-759.
5. Blais, J. D., V. Filipenko, M. Bi, H. P. Harding, D. Ron, C. Koumenis, B. G. Wouters, and J. C. Bell. 2004. Activating transcription factor 4 is transla-tionally regulated by hypoxic stress. Mol. Cell. Biol. 24:7469-7482.
6. Bonner, W. M., C. E. Redon, J. S. Dickey, A. J. Nakamura, O. A. Sedelni-kova, S. Solier, and Y. Pommier. 2008. γH2AX and cancer. Nat. Rev. Cancer 8:957-967.
7. Brizel, D. M., G. S. Sibley, L. R. Prosnitz, R. L. Scher, and M. W. Dewhirst. 1997. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38:285-289.
8. Brown, J. M., and W. R. Wilson. 2004. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4:437-447.
9. Budanov, A. V., and M. Karin. 2008. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134:451-460.
10. Bunz, F., A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J. P. Brown, J. M. Sedivy, K. W. Kinzler, and B. Vogelstein. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501.
11. Bykov, V. J., and K. G. Wiman. 2003. Novel cancer therapy by reactivation of the p53 apoptosis pathway. Ann. Med. 35:458-465.
12. Carroll, V. A., and M. Ashcroft. 2006. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res. 66:6264-6270.
13. Dever, T. E. 2002. Gene-specific regulation by general translation factors. Cell 108:545-556.
14. E1-Deiry, W. S. 2003. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22:7486-7495.
15. Feng, Z., W. Hu, E. de Stanchina, A. K. Teresky, S. Jin, S. Lowe, and A. J. Levine. 2007. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 67:3043-3053.
16. Feng, Z., W. Hu, G. Rajagopal, and A. J. Levine. 2008. The tumor suppressor p53: cancer and aging. Cell Cycle 7:842-847.
17. Feng, Z., H. Zhang, A. J. Levine, and S. Jin. 2005. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. USA 102: 8204-8209.
18. Fernando, N. H., and H. I. Hurwitz. 2004. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 9(Suppl. 1):11-18.
19. Foster, B. A., H. A, Coffey, M. J. Morin, and F. Rastinejad. 1999. Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507-2510.
20. Graeber, T. G., C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe, and A. J. Giaccia. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91.
21. Hammond, E. M, M. J. Dorie, and A. J. Giaccia. 2003. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J. Biol. Chem. 278:12207-12213.
22. Hurwitz, H. 2004. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin. Colorectal Cancer 4(Suppl. 2):S62-S68.
23. Issaeva, N., P. Bozko, M. Enge, M. Protopopova, L. G. Verhoef, M. Masucci, A. Pramanik, and G. Selivanova. 2004. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10:1321-1328.
24. 2 sensing. Science 292:464-468.
25. 2-regulated prolyl hydroxylation. Science 292:468-472.
26. Jimenez, G. S, S. H. Khan, J. M. Stommel, and G. M. Wahl. 1999. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 18:7656-7665.
27. Kaluzová, M., S. Kaluz, M. I. Lerman, and E. J. Stanbridge. 2004. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-lα in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol. Cell. Biol. 24:5757-5766.
28. Kao, J., M. T. Milano, A. Javaheri, M. C. Garofalo, S. J. Chmura, R. R. Weichselbaum, and S. J. Kron. 2006. γ-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr. Cancer Drug Targets 6:197-205.
29. Koumenis, C. 2006. ER stress, hypoxia tolerance and tumor progression. Curr. Mol. Med. 6:55-69.
30. Koumenis, C., C. Naczki, M. Koritzinsky, S. Rastani, A. Diehl, N. Sonen-berg, A. Koromilas, and B. G. Wouters. 2002. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2α. Mol. Cell. Biol. 22:7405-7416.
31. Krajewski, M, P. Ozdowy, L. D'Silva, U. Rothweiler, and T. A, Holak. 2005. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat. Med. 11:1135-1137.
32. Laughner, E., P. Taghavi, K. Chiles, P. C. Mahon, and G. L. Semenza. 2001. HER2 (neu) signaling increases the rate of hypoxia-inducible factor lα (HIF-lα) synthesis: novel mechanism for HIF-1-mediated vascular endothe-lial growth factor expression. Mol. Cell. Biol. 21:3995-4004.
33. Lowe, S. W., and A. W. Lin. 2000. Apoptosis in cancer. Carcinogenesis 21:485-495.
34. Mayer, E. L., N. U. Lin, and H. J. Burstein. 2007. Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J. Natl. Compr. Cancer Netw. 5:314-323.
35. Moeller, B. J., M. R. Dreher, Z. N. Rabbani, T. Schroeder, Y. Cao, C. Y. Li, and M. W. Dewhirst. 2005. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8:99-110.
36. Nakano, K., E. Balint, M. Ashcroft, and K. H. Vousden. 2000. A ribonucle-otide reductase gene is a transcriptional target of p53 and p73. Oncogene 19:4283-4289.
37. Nieves-Neira, W., M. I. Rivera, G. Kohlhagen, M. L. Hursey, P. Pourquier, E. A. Sausville, and Y. Pommier. 1999. DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Mol. Pharmacol. 56:478-484.
38. Nordsmark, M., M. Overgaard, and J. Overgaard. 1996. Pretreatment oxy-genation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41:31-39.
39. Ravi, R., B. Mookerjee, Z. M. Bhujwalla, C. H. Sutter, D. Artemov, Q. Zeng, L. E. Dillehay, A. Madan, G. L. Semenza, and A, Bedi. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14:34-44.
40. Rivera, M. I., S. F. Stinson, D. T. Vistica, J. L. Jorden, S. Kenney, and E. A, Sausville. 1999. Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Bio-chem. Pharmacol. 57:1283-1295.
41. Salnikow, K., M. Costa, W. D. Figg, and M. V. Blagosklonny. 2000. Hyper-inducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res. 60:5630-5634.
42. Semenza, G. L., L. A. Shimoda, and N. R. Prabhakar. 2006. Regulation of gene expression by HIF-1. Novartis Found. Symp. 272:2-8.
43. Stempien-Otero, A., A, Karsan, C. J. Cornejo, H. Xiang, T. Eunson, R. S. Morrison, M. Kay, R. Winn, and J. Harlan. 1999. Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. J. Biol. Chem. 274:8039-8045.
44. Thomas, G. V., C. Tran, I. K. Mellinghoff, D. S. Welsbie, E. Chan, B. Fueger, J. Czernin, and C. L. Sawyers. 2006. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12:122-127.
45. Tovar, C., J. Rosinski, Z. FilipoviC., B. Higgins, K. Kolinsky, H. Hilton, X. Zhao, B. T. Vu, W. Qing, K. Packman, O. Myklebost, D. C. Heimbrook, and L. T. Vassilev. 2006. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. USA 103:1888-1893.
46. United Kingdom Co-ordinating Committee on Cancer Research. 1998. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br. J. Cancer 77(Suppl. l):1-10.
47. Vassilev, L. T., B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. FilipoviC., N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E. A, Liu. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848.
48. Vogelstein, B., and K. W. Kinzler. 2004. Cancer genes and the pathways they control. Nat. Med. 10:789-799.
49. Williams, K. J., B. A, Telfer, D. Xenaki, M. R. Sheridan, I. Desbaillets, H. J. Peters, D. Honess, A. L. Harris, G. U. Dachs, A. van der Kogel, and I. J. Stratford. 2005. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother. Oncol. 75:89-98.
50. Wouters, B. G., and M. Koritzinsky. 2008. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 8:851-864.
51. Zhang, F., R. B. Hamanaka, E. Bobrovnikova-Marjon, J. D. Gordan, M. S. Dai, H. Lu, M. C. Simon, and J. A. Diehl. 2006. Ribosomal stress couples the unfolded protein response to p53-dependent cell cycle arrest. J. Biol. Chem. 281:30036-30045.